Clinical Trials

80 enrolled

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT06184750 2026-03-18

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT06075953 2026-03-16

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

400 enrolled

Phase 2 Not yet recruiting

Carcinoma, Intraductal, Noninfiltrating

NCT07287098 2026-03-16

preEMBER

600 enrolled

Breast Neoplasms

NCT06434064 2026-03-02

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

30 enrolled

Triple Negative Breast Neoplasms

NCT06179303 2026-02-27

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

60 enrolled

Anatomic Stage III Breast Cancer AJCC v8

NCT04059484 2026-02-24

AMEERA-3

367 enrolled 30 charts

Breast Cancer Metastatic

NCT00003042 2026-02-20

Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer

41 enrolled 9 charts

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT06348134 2026-02-17

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

74 enrolled

Breast Neoplasms

NCT05101564 2026-02-12

Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer

19 enrolled 10 charts

Breast Neoplasms

NCT02747004 2026-02-06

Next MONARCH 1

234 enrolled 20 charts

Breast Neoplasms

NCT04570956 2026-01-23

Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk

65 enrolled

Breast Carcinoma In Situ, Breast Neoplasms

NCT03879577 2026-01-21

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

53 enrolled 13 charts

Breast Neoplasms

NCT02668666 2026-01-20

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

49 enrolled 14 charts

Breast Neoplasms

NCT06001762 2026-01-16

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

90 enrolled

Breast Neoplasms

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT05150652 2026-01-07

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

8 enrolled

Breast Neoplasms

NCT05501704 2026-01-07

ETHAN - ET for Male BC

60 enrolled

Breast Neoplasms, Male

NCT01196936 2026-01-05

LDTam

84 enrolled 17 charts

Breast Neoplasms

NCT05035836 2025-12-22

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

20 enrolled

Breast Neoplasms

NCT02630693 2025-11-25

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

180 enrolled 14 charts

Breast Neoplasms

NCT06364267 2025-11-18

BabyTears

140 enrolled

Breast Neoplasms

NCT04569747 2025-11-13

ADEPT

375 enrolled

Breast Neoplasms

NCT06033092 2025-08-28

TOLERANT

Phase 2 Not yet recruiting

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating

NCT07101159 2025-08-03

Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients

Breast Neoplasms

NCT04300790 2025-07-29

METALLICA

69 enrolled

BreastEndocrine

Breast Neoplasms, Hyperglycemia, Neoplasm Metastasis, Multiple Endocrine Neoplasia Type 1

NCT02476786 2025-07-28

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

50 enrolled

Breast Neoplasms

NCT05472792 2025-05-23

CAMERAN

90 enrolled

Breast Neoplasms

NCT02764541 2025-05-07

Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)

195 enrolled 26 charts

Breast Neoplasms, Carcinoma, Lobular

NCT02040857 2025-04-29

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

162 enrolled 12 charts

Breast Neoplasms

NCT03219476 2025-04-29

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

37 enrolled 10 charts

Breast Neoplasms

NCT03161353 2025-04-23

PHERGain

377 enrolled

Breast Neoplasms

NCT03346200 2025-03-07

KARISMA2

1,440 enrolled 14 charts

Breast Neoplasms, Risk Reduction Behavior

NCT03691493 2025-02-17

ASPIRE

36 enrolled 17 charts

Breast Neoplasms

NCT02993159 2024-12-18

Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

100 enrolled 15 charts

Carcinoma, Intraductal, Noninfiltrating

NCT04985266 2024-12-05

TRAK-ER

1,100 enrolled

ER+ Breast Cancer

NCT04129216 2024-05-07

The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer

30 enrolled 10 charts

Breast Neoplasms

NCT04997941 2024-04-23

MORE-T

238 enrolled

Premenopausal Breast Cancer

NCT03272477 2024-04-17

TP-II

257 enrolled

Breast Neoplasms

NCT03906669 2023-11-22

WinPro

Phase 2 Unknown

Breast Neoplasms

NCT01298713 2023-09-06

Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer

111 enrolled

Breast Neoplasms

NCT04190056 2023-08-31

Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer

1 enrolled 4 charts

Anatomic Stage IV Breast Cancer AJCC v8

NCT01124695 2023-06-29

Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer

124 enrolled 14 charts

Breast Neoplasms

NCT05133674 2022-05-25

Therapeutic Dose Monitoring (TDM) of Tamoxifen

Phase 2 Unknown

40 enrolled

Breast Neoplasms

NCT04666961 2022-04-22

HORNEO01

262 enrolled

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT02269670 2022-04-05

Phase II Study of Everolimus Beyond Progression

3 enrolled 4 charts

Breast Neoplasms

NCT02384239 2022-03-16

A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer

70 enrolled 16 charts

Breast Neoplasms

NCT02603679 2021-08-03

PREDIX LumB

181 enrolled

Breast Neoplasms

NCT01220076 2021-03-12

TAM

140 enrolled

Non Metastatic Breast Cancer

NCT02395627 2020-07-07

Reversing Therapy Resistance With Epigenetic-Immune Modification

38 enrolled 18 charts